Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8

Abstract

Sterically stabilized liposome (SL) modified with 2E8 monoclonal antibody (2E8-SL) was prepared in order to evaluate its targeting ability and internalization efficiency against tumor cells with high expression of CD19. 2E8 was coupled to the surface of SL using post-insertion technique. The shape of liposomes was observed under a transmission electronic microscope. The average size of liposomes was determined by using the Zetasizer instrument. The binding and internalization of 2E8-SL against tumor cells with higher expression of CD19 were tested by flow cytometry and confocal microscopy. The mean diameter of 2E8-SL was 121.25 nm. 2E8-SL was stable after up to 24 days in various buffers. 2E8-SL showed specific binding to tumor cells with high expression of CD19, including B cells in peripheral blood mononuclear cells (PBMCs). 2E8-SL could efficiently internalize into Nalm6 cells with CD19 high expression. It is suggested that 2E8-SL may serve as useful delivery carrier of anti-cancer drugs targeting to hematological malignant tumors with CD19 high expression.

Keywords

targeting / liposome / anti-CD19 antibody / hematologic malignant tumors

References

[1] SapraP., TyagiP., AllenT.M.. Ligand-targeted liposomes for cancer treatment. Current Drug Delivery, 2005, 2(4): 369-381

[2] AllenT.M.. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2002, 2(10): 750-763

[3] TorchilinV.P.. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J, 2007, 9(2): 128-147

[4] UckunF.M., JaszczW., AmbrusJ.L., et al. . Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 1988, 71(1): 13-29

[5] KongY., YoshidaS., SaitoY., et al. . CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia, 2008, 22(6): 1207-1213

[6] LopesD., MenezesD.E.. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma Cell. J Liposome Res, 1999, 9(2): 199-228

[7] PastorinoF., BrignoleC., MarimpietriD., et al. . Doxorubicin-loaded Fab’ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res, 2003, 63(1): 86-92

[8] SapraP., MoaseE.H., MaJ.. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab’ fragments. Clin Cancer Res, 2004, 10(3): 1100-1111

[9] SapraP., AllenT.M.. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res, 2002, 62(24): 7190-7194

[10] SapraP., AllenT.M.. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res, 2004, 10(7): 2530-2537

[11] TangY.M., GuoS.F.. The preparation and application of ZCH-4-2E8: a monoclonal antibody specific targeting to B lymphocyte. J Zhejiang Med Univ (Chinese), 1994, 23(6): 246-248

[12] LiL.X., TangY.M., ZhangH.Z., et al. . Preparation of the immunotoxin 2E8-norcantharidin and its targeting killing effect in vitro. Zhonghua Er Ke Za Zhi (Chinese), 2008, 46(7): 493-497

[13] WuJ.M., RenT.C.. The preparation of characters of liposome containing norcnatharidin. Chin Phar J, 2001, 19(40): 1485-1487

[14] IdenD.L., AllenT.M.. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta, 2001, 1513(2): 207-216

[15] CunninghamD., HumbletY., SienaS., et al. . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351(4): 337-345

[16] HurwitzH.I., FehrenbacherL., HainsworthJ.D., et al. . Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 2005, 23(15): 3502-3508

[17] ZhouY., DrummondD.C., ZouH., et al. . Impact of Single-chain Fv antibody fragment affinity on Nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol, 2007, 371(4): 934-947

[18] YangT., ChoiM.K., CuiF.D., et al. . Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release, 2007, 120(3): 169-177

[19] Lopes de MenezesD.E., PilarskiL.M., AllenT.M.. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma, 1998, 58(15): 3320-3330

[20] AsaiT., ShimizuK., KondoM., et al. . Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett, 2002, 520(1–3): 167-170

[21] GabizonA., HorowitzA.T., GorenD., et al. . In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res, 2003, 9(17): 6551-6559

[22] SapraP., AllenT.M.. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res, 2003, 42(5): 439-462

[23] LuJ., JeonE., LeeB.S., et al. . Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes. J Control Release, 2006, 110(3): 505-513

[24] PanH., NiuG.Q., PanJ., LuW.Y.. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody. Yao Xue Xue Bao (Chinese), 2006, 41(6): 506-512

[25] ChengW.W., DasD., SureshM., et al. . Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta, 2007, 1768(1): 21-29

[26] Lopes de MenezesD.E., PilarskiL.M., et al. . Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta, 2002, 1466(1–2): 205-220

[27] HarataM., SodaY., TaniK., et al. . CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood, 2004, 104(5): 1442-1449

[28] LuqueR., BrievaJ.A., MorenoA., et al. . Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients—diagnostic and clinical implications. Clin Exp Immunol, 1998, 112(3): 410-418